These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30875673)

  • 41. Effect of Mirtazapine Treatment on Serum Levels of Brain-Derived Neurotrophic Factor and Tumor Necrosis Factor-α in Patients of Major Depressive Disorder with Severe Depression.
    Gupta R; Gupta K; Tripathi AK; Bhatia MS; Gupta LK
    Pharmacology; 2016; 97(3-4):184-8. PubMed ID: 26854819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorder.
    Xu Y; Liang J; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
    Int Immunopharmacol; 2023 May; 118():110108. PubMed ID: 37004349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of 4-week antidepressant outcome in patients with first-episode major depressive disorder: An ROC curve analysis.
    Zhou Y; Zhang Z; Wang C; Lan X; Li W; Zhang M; Lao G; Wu K; Chen J; Li G; Ning Y
    J Affect Disord; 2022 May; 304():59-65. PubMed ID: 35172174
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only.
    Haghighi M; Salehi I; Erfani P; Jahangard L; Bajoghli H; Holsboer-Trachsler E; Brand S
    J Psychiatr Res; 2013 Jul; 47(7):908-15. PubMed ID: 23583029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
    Kasper S; Ebert B; Larsen K; Tonnoir B
    Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term escitalopram treatment normalizes aberrant self-referential processing in major depressive disorder.
    Komulainen E; Heikkilä R; Nummenmaa L; Raij TT; Harmer CJ; Isometsä E; Ekelund J
    J Affect Disord; 2018 Aug; 236():222-229. PubMed ID: 29747140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive-Compulsive Disorder Rats.
    Guo HR; Huang BL; Wang YL; Zhang YY; Ma QG; Lv PP; Ren YM
    Cell Mol Neurobiol; 2020 Aug; 40(6):991-997. PubMed ID: 31927718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cross-trial prediction of treatment outcome in depression: a machine learning approach.
    Chekroud AM; Zotti RJ; Shehzad Z; Gueorguieva R; Johnson MK; Trivedi MH; Cannon TD; Krystal JH; Corlett PR
    Lancet Psychiatry; 2016 Mar; 3(3):243-50. PubMed ID: 26803397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mean platelet volume in patients with major depression: effect of escitalopram treatment.
    Ataoglu A; Canan F
    J Clin Psychopharmacol; 2009 Aug; 29(4):368-71. PubMed ID: 19593177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress.
    Schulte-Herbrüggen O; Fuchs E; Abumaria N; Ziegler A; Danker-Hopfe H; Hiemke C; Hellweg R
    J Neurosci Res; 2009 Aug; 87(11):2551-60. PubMed ID: 19360902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
    Muhonen LH; Lahti J; Alho H; Lönnqvist J; Haukka J; Saarikoski ST
    Psychiatry Res; 2011 Mar; 186(1):53-7. PubMed ID: 20800901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The serum protein levels of the tPA-BDNF pathway are implicated in depression and antidepressant treatment.
    Jiang H; Chen S; Li C; Lu N; Yue Y; Yin Y; Zhang Y; Zhi X; Zhang D; Yuan Y
    Transl Psychiatry; 2017 Apr; 7(4):e1079. PubMed ID: 28375203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
    Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
    J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
    Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G;
    JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.
    Dong C; Zhang JC; Yao W; Ren Q; Yang C; Ma M; Han M; Saito R; Hashimoto K
    Pharmacol Biochem Behav; 2016 May; 144():7-12. PubMed ID: 26892759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation.
    Xiaoling Z; Yunping H; Yingdong L
    Pak J Pharm Sci; 2018 May; 31(3(Special)):1115-1118. PubMed ID: 29737292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.